| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P50 | author | Tzu-Chieh Lin | Q87613132 |
| Andrew Hresko | Q89834465 | ||
| Daniel H Solomon | Q91503755 | ||
| P2860 | cites work | Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis. | Q38052651 |
| The cost burden of multiple sclerosis in the United States: a systematic review of the literature | Q38083101 | ||
| Utilization and costs of medical services and prescription medications for rheumatoid arthritis among recipients covered by a state Medicaid program: a retrospective, cross-sectional, descriptive, database analysis | Q38458850 | ||
| Impact of Switching From an Initial Tumor Necrosis Factor Inhibitor on Health Care Resource Utilization and Costs Among Patients With Rheumatoid Arthritis | Q40913525 | ||
| The clinical and economic burden of chronic obstructive pulmonary disease in the USA. | Q41548699 | ||
| Direct medical expenditure associated with rheumatoid arthritis in a nationally representative sample from the medical expenditure panel survey | Q43461275 | ||
| Changes in utilization and costs for patients with rheumatoid arthritis, 1997 to 2006. | Q44253853 | ||
| Prevalence of specific types of arthritis and other rheumatic conditions in the ambulatory health care system in the United States, 2001-2005. | Q44914209 | ||
| Societal cost of rheumatoid arthritis patients in the US. | Q48956161 | ||
| Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. | Q50732154 | ||
| How large are the productivity losses in contemporary patients with RA, and how soon in relation to diagnosis do they develop? | Q51160559 | ||
| Biologic disease-modifying drug treatment patterns and associated costs for patients with rheumatoid Arthritis. | Q51168531 | ||
| Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. | Q53725487 | ||
| Meta-analysis of prevalence | Q57243585 | ||
| Medicaid prescription formulary restrictions and arthritis treatment costs | Q81358204 | ||
| Retrospective study of the costs of care during the first year of therapy with etanercept or infliximab among patients aged > or =65 years with rheumatoid arthritis | Q81888359 | ||
| Out-of-pocket expenses and their burden in patients with rheumatoid arthritis | Q84820003 | ||
| Factors associated with the initiation of biologic disease-modifying antirheumatic drugs in Texas Medicaid patients with rheumatoid arthritis | Q87246641 | ||
| Economic costs of diabetes in the U.S. in 2012 | Q22241287 | ||
| Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data | Q31116692 | ||
| Economic burden of rheumatoid arthritis: a systematic review | Q33831406 | ||
| The economic consequences of rheumatoid arthritis: analysis of Medical Expenditure Panel Survey 2004, 2005, and 2006 data | Q34121437 | ||
| A review of the direct costs of rheumatoid arthritis: managed care versus fee-for-service settings | Q34398912 | ||
| Rheumatoid arthritis: direct and indirect costs | Q35979186 | ||
| Time trends in medication use and expenditures in older patients with rheumatoid arthritis | Q36204927 | ||
| Indirect costs of rheumatoid arthritis | Q36842488 | ||
| Systematic review: the costs of ulcerative colitis in Western countries | Q37671838 | ||
| Economic consequences and potential benefits | Q37964322 | ||
| P433 | issue | 10 | |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| systematic review | Q1504425 | ||
| P304 | page(s) | 1431-1438 | |
| P577 | publication date | 2018-10-01 | |
| P1433 | published in | Arthritis Care and Research | Q15754720 |
| P1476 | title | Medical Care Costs Associated With Rheumatoid Arthritis in the US: A Systematic Literature Review and Meta-Analysis | |
| P478 | volume | 70 |
Search more.